Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 17

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 17
---
 of shares of Common Stock to Keystone under the Keystone Purchase Agreements will depend on
a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the Common
Stock and determinations by us as to the appropriate sources of funding and our operations.

Concurrent with the execution
of the New Keystone Purchase Agreement, we entered into the New Keystone Registration Rights Agreement, pursuant to which we agreed to
provide Keystone with customary registration rights related to the shares issued under the New Keystone Purchase Agreement.

<div align='center'>1</div>

Third PIPE Financing

On September 25, 2024, we
consummated a private placement of 2,853 shares of Series C Preferred Stock and 81,752 Series C Warrants pursuant to the Third Securities
Purchase Agreement, by and among us and certain PIPE Investors for aggregate cash proceeds of approximately $1.25 million.

In connection with the Third
PIPE Financing, we entered into the Third PIPE Registration Rights Agreement with the PIPE Investors. The terms of the Third PIPE Registration
Rights Agreement require us to register the number of shares of Common Stock equal to the sum of (i) 250% of the maximum number of Common
Stock issuable upon conversion of the Series C Preferred Stock (assuming for purposes hereof that (x) the Series C Preferred Stock is
convertible at the Alternate Conversion Price (as defined in the Series C Certificate of Designations) assuming an Alternate Conversion
Date (as defined in the Series C Certificate of Designations) of such date of determination, and (y) any such conversion shall not take
into account any limitations on the conversion of the Series C Preferred Stock set forth in the Series C Certificate of Designations)
and (ii) the maximum number of Warrant Common Shares issuable upon exercise of the Warrants (without taking into account any limitations
on the exercise of the Warrants set forth therein).

Investigational New Drug Application

On June 28, 2024, we submitted
an investigational new drug application (“IND”) for its product candidate, CER-1236, to the FDA. On July 26, 2024, we were
informed by the FDA that it has placed a clinical hold on the IND. The FDA indicated that the clinical hold has been placed as a result
of insufficient data provided with regard to two issues within pharmacology and toxicology of CER-1236. The FDA indicated that, within
30